Extending qualified research institutions beyond the investigational new drug application
Journal of Clinical and Translational Science · 2026 · 10 (1)
DOI: 10.1017/cts.2026.10861 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical and Translational Science, online erschienen am 19.11.2026. Verfasst von Jerry A. Krishnan und 3 weiteren Autor:innen. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
To renew US competitiveness in clinical trials, the federal government launched Operation TrialBlazer in June 2026. Its proposed Expedited-IND Acceleration Pilot would enlist Qualified Research Institutions (QRIs) to help sponsors prepare investigational new drug (IND) applications for first-in-human studies. Because a successful IND does not guarantee a completed trial, we propose a testable, expanded QRI framework to support trial execution. First, build QRIs with standing networks that reuse contracts, data systems, and staff to lower marginal costs and enable performance measurement. Second, require QRIs to have capabilities that enable and assess site performance: human factors expertise and stakeholder co-design in protocol development; leading (not only lagging) indicators of trial performance; efficient, proportionate execution that preserves rigor and safety; and oversight by an independent trial performance monitoring board empowered to conduct in-person observations and interviews at trial sites. Third, qualify QRIs on demonstrated performance, with reciprocal obligations for sponsors. Fourth, renew QRIs using publicly reported, case-mix-adjusted metrics. The Food and Drug Administration and National Institutes of Health should jointly fund evaluations of this framework. Extending QRIs across the trial lifecycle is more likely than a pre-IND role alone to close the time and cost gaps that send research overseas.
Zitieren
APA
Krishnan, J. A., Advani, R., Palmer, S. M., & Musick, H. R. (2026). Extending qualified research institutions beyond the investigational new drug application. Journal of Clinical and Translational Science, 10(1). https://doi.org/10.1017/cts.2026.10861
Vancouver
Krishnan JA, Advani R, Palmer SM, Musick HR. Extending qualified research institutions beyond the investigational new drug application. Journal of Clinical and Translational Science. 2026;10(1). doi:10.1017/cts.2026.10861
BibTeX
@article{Krishnan2026,
author = {Krishnan, Jerry A. and Advani, Rajiv and Palmer, Scott M. and Musick, Hugh R.},
title = {Extending qualified research institutions beyond the investigational new drug application},
journal = {Journal of Clinical and Translational Science},
year = {2026},
volume = {10},
number = {1},
doi = {10.1017/cts.2026.10861}
}
EUVIMED